Literature DB >> 9668055

Rac and Cdc42 are potent stimulators of E2F-dependent transcription capable of promoting retinoblastoma susceptibility gene product hyperphosphorylation.

O Gjoerup1, J Lukas, J Bartek, B M Willumsen.   

Abstract

The Rho family of GTPases plays an important and diverse role in reorganization of the actin cytoskeleton, transcriptional regulation, and multiple aspects of cell growth. Our study has examined their potential links to the cell cycle machinery. We find that constitutively active mutants of Rac and Cdc42, but not Rho, are potent inducers of E2F transcriptional activity in NIH 3T3 fibroblasts. Furthermore, activated Rac and Cdc42, but again not Rho, are capable of inducing cyclin D1 accumulation and pRB hyperphosphorylation in serum-deprived cells, outlining one route leading to enhanced E2F-mediated transcription. The inhibitory effect of the cyclin-dependent kinase inhibitors, p16(ink4), p21(cip1), and p27(cip) on Rac/Cdc42-mediated E2F transcription corroborates a role for pRB family members and their functional inactivation by cyclin-dependent kinases in generating E2F activity. While the up-regulation of E2F transcriptional activity by Rac or Cdc42, not Rho, suffices for entry into S phase and DNA synthesis in Rat-1 R12 cells, this is clearly not the case in NIH 3T3, where additional requirements must exist.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9668055     DOI: 10.1074/jbc.273.30.18812

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  The insert region of Rac1 is essential for membrane ruffling but not cellular transformation.

Authors:  A E Karnoub; C J Der; S L Campbell
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  The Rho GTPase Cdc42 is required for primary mammary epithelial cell morphogenesis in vitro.

Authors:  Kristi Bray; Cord Brakebusch; Tracy Vargo-Gogola
Journal:  Small GTPases       Date:  2011-09-01

3.  Dissecting the role of endothelial SURVIVIN DeltaEx3 in angiogenesis.

Authors:  Hugo Caldas; Jason R Fangusaro; Daniel R Boué; Michael P Holloway; Rachel A Altura
Journal:  Blood       Date:  2006-10-12       Impact factor: 22.113

Review 4.  Cdc42 in oncogenic transformation, invasion, and tumorigenesis.

Authors:  Kristy Stengel; Yi Zheng
Journal:  Cell Signal       Date:  2011-04-16       Impact factor: 4.315

Review 5.  Mitogenic signaling and the relationship to cell cycle regulation in astrocytomas.

Authors:  A Besson; V W Yong
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

6.  Cyclin D1 regulates cellular migration through the inhibition of thrombospondin 1 and ROCK signaling.

Authors:  Zhiping Li; Chenguang Wang; Xuanmao Jiao; Yinan Lu; Maofu Fu; Andrew A Quong; Chip Dye; Jianguo Yang; Maozheng Dai; Xiaoming Ju; Xueping Zhang; Anping Li; Peter Burbelo; E Richard Stanley; Richard G Pestell
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

7.  A dual role of the GTPase Rac in cardiac differentiation of stem cells.

Authors:  Michel Pucéat; Pierre Travo; Mark T Quinn; Philipe Fort
Journal:  Mol Biol Cell       Date:  2003-03-20       Impact factor: 4.138

8.  Cell attachment to the extracellular matrix induces proteasomal degradation of p21(CIP1) via Cdc42/Rac1 signaling.

Authors:  Wenjie Bao; Minna Thullberg; Hongquan Zhang; Anatoli Onischenko; Staffan Strömblad
Journal:  Mol Cell Biol       Date:  2002-07       Impact factor: 4.272

Review 9.  Neurofibromatosis type 2 protein, NF2: an uncoventional cell cycle regulator.

Authors:  Sarah Beltrami; Richard Kim; Jennifer Gordon
Journal:  Anticancer Res       Date:  2013-01       Impact factor: 2.480

10.  Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion.

Authors:  Alaina K Fournier; Latoya E Campbell; Paola Castagnino; Wendy F Liu; Betty M Chung; Valerie M Weaver; Christopher S Chen; Richard K Assoian
Journal:  J Cell Sci       Date:  2008-01-15       Impact factor: 5.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.